Extended Data Fig. 2: MMP13 knockdown in PTOA joints by i.v. delivery of siMMP13<(EG18L)2.
a, Mmp13 mRNA was measured by qRT-PCR in healthy and PTOA knees of mice 5 days after i.v. delivery of siMMP13<(EG18L)2, siMMP13-Chol, or free siMMP13 (5 and 10 mg/kg, where indicated). Timeline for mechanical knee loading and treatment is shown in Extended Data Fig 1. b, Mmp13 mRNA was measured by qRT-PCR in PTOA mouse knees 5 days after i.v., i.a., or subcutaneous siMMP13<(EG18L)2 delivery at the doses indicated. N = 5-6. c, Mmp13 mRNA was measured by qRT-PCR in PTOA mouse knees 5 days after subcutaneous siMMP13<(EG18L)2 delivery at the doses indicated. N = 5-6. d-e, MMP13 IHC in PTOA knees (d), liver (e, top), and kidneys (e, bottom) 5 days after i.v. delivery (10 mg/kg) of siMMP13<(EG18L)2, siMMP13-Chol, free siMMP13, or no treatment. f, Relative Mmp13 mRNA expression in liver and kidneys of untreated mice (relative to PTOA knee Mmp13 levels). N = 3. g, Relative Mmp13 mRNA in kidneys, 5 days post-injection with 10 mg/kg siMMP13<(EG18L)2 or free siMMP13, vs. untreated controls. N = 3. For all panels: Error bars indicate standard deviation of biological replicates.
